This observational study confirms that the rate of structural damage progression in clinical remission is decreased taking biologics compared to synthetic DMARD. However, while the difference is statistically significant it is probably not relevant from a clinical perspective. PubMed, J Rheumatol, 2014 Aug;41(8):1576-82. (Also see: Rheumatoid Arthritis Treatments, Biologic Agents and Disease-modifying Antirheumatic Drugs)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.